ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2023

Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study.

Luis Paz-Ares et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.